Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Asset Writedowns and Impairment (2016 - 2020)

Harvard Bioscience (HBIO) has disclosed Asset Writedowns and Impairment for 11 consecutive years, with $787000.0 as the latest value for Q4 2020.

  • On a quarterly basis, Asset Writedowns and Impairment rose 160.54% to $787000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $787000.0, a 22.92% decrease, with the full-year FY2020 number at $787000.0, up 687.0% from a year prior.
  • Asset Writedowns and Impairment was $787000.0 for Q4 2020 at Harvard Bioscience, up from -$4000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.0 million in Q3 2019 to a low of -$1.3 million in Q4 2019.
  • A 5-year average of $150647.1 and a median of $22000.0 in 2018 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: soared 22633.33% in 2016, then plummeted 6009.09% in 2019.
  • Harvard Bioscience's Asset Writedowns and Impairment stood at -$44000.0 in 2016, then tumbled by 150.0% to -$110000.0 in 2017, then skyrocketed by 120.0% to $22000.0 in 2018, then tumbled by 6009.09% to -$1.3 million in 2019, then soared by 160.54% to $787000.0 in 2020.
  • Per Business Quant, the three most recent readings for HBIO's Asset Writedowns and Impairment are $787000.0 (Q4 2020), -$4000.0 (Q3 2020), and $4000.0 (Q1 2020).